Abstract
Using MRI, we measured disease activity and brain atrophy in nine multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT) for a mean follow up of 63 months. We show that AHSCT is associated to a longlasting suppression of inflammation and to a marked decrease of the rate of brain atrophy after the second year following treatment.
MeSH terms
-
Adult
-
Age of Onset
-
Atrophy
-
Brain / pathology
-
Cyclophosphamide / therapeutic use
-
Follow-Up Studies
-
Hematopoietic Stem Cell Mobilization / methods
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Inflammation / prevention & control
-
Magnetic Resonance Imaging
-
Middle Aged
-
Multiple Sclerosis / pathology*
-
Multiple Sclerosis / therapy*
-
Transplantation, Autologous